KIM, EUN JI,金银枝,金銀枝,PARK, HYE JUNG,朴譓晶,YOUN, SANG JUN,尹相竣,PARK, HYO JU,朴孝珠,HONG, MIN JU,洪民主,PYO, HYO JU,表佼珠,JUNG, YUN AH,郑贇娥,鄭贇娥,PARK, HYUN WOOK,朴显旭,朴顯旭,KIM, YUN JUNG,金润贞,金潤貞,SONG,
申请号：
TW103106464
公开号：
TW201434463A
申请日:
2014.02.26
申请国别(地区):
TW
年份:
2014
代理人:
摘要：
The present invention relates to a formulation of voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof which is provided for the reduction, in a substantially equivalent or increased amount compared to single administration of metformin, of HbAlc levels, fasting and postprandial blood glucose levels and postprandial blood glucose variation, or glycemic variability and also the reduction of the frequency of hypoglycemia, cardiovascular complications, and gastrointestinal complications in a patient with no prior experience of anti-diabetes medication or a patient in the early stage of type 2 diabetes showing a HbAlc (%) level of 7 to 11%, and ultimately, is able to effectively treat diabetes in patients in the early stage of type 2 diabetes and to minimize adverse effects, side-effects, and risk of complications.本發明係關於一種伏格列波糖(voglibose)或其醫藥學上可接受之鹽及二甲雙胍(metformin)或其醫藥學上可接受之鹽的調配物，其係提供來相較於單一投與二甲雙胍，以實質上相等或增加之量降低HbAlc含量、空腹及餐後血糖含量以及餐後血糖變化或血糖可變性，且亦降低先前未經受抗糖尿病藥物之患者或顯示HbAlc(%)含量為7至11%之處於早期2型糖尿病之患者之低血糖、心血管併發症及胃腸併發症的頻率，且最後，能夠有效治療處於早期2型糖尿病之患者之糖尿病以及使不利效應、副作用及併發症之風險最小。
